2. Vías de señalización
  3. Metabolic Enzyme/Protease
    Vitamin D Related/Nuclear Receptor
  4. LXR

LXR

Liver X receptor

LXR

Related Products

PDF 0.41 MB

LXRs (Liver X Receptor α and β) are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors. LXRs are oxysterol-activated transcription factors that upregulate a suite of genes that together promote coordinated mobilization of excess cholesterol from cells and from the body. The LXRs, like other nuclear receptors, are anti-inflammatory, inhibiting signal-dependent induction of pro-inflammatory genes by nuclear factor-κB, activating protein-1, and other transcription factors.

LXRα is expressed predominately in some tissues, including the liver, kidney, macrophages, and adipose tissue. However, LXRβ is ubiquitously expressed. Activating LXRα (mainly expressed in liver) results in high triglyceride production, and growing evidence suggests that selective LXRβ agonists can reduce this side effect.

Cat. No. Nombre del producto Efecto Pureza Chemical Structure
  • HY-176236
    Lipophagy inducer 1
    		Modulator
    Lipophagy inducer 1 is a lipophagy inducer. Lipophagy inducer 1 has activity of reducing lipid droplet accumulation and rescuing cell death. Lipophagy inducer 1 exerts its effects by activating lipophagy, increasing steady-state autophagosome and regulating the LXR signaling pathway. Lipophagy inducer 1 can be used in the study of diabetic nephropathy (DKD) and other diseases related to lipid metabolism disorders.
    Lipophagy inducer 1
  • HY-N0835R
    (20S)-Protopanaxatriol (Standard)
    		Inhibitor
    (20S)-Protopanaxatriol (Standard) is the analytical standard of (20S)-Protopanaxatriol. This product is intended for research and analytical applications. (20S)-Protopanaxatriol is a metabolite of ginsenoside. (20S)-Protopanaxatriol works through the glucocorticoid receptor (GR) and estrogen receptor (ER), and is also a LXRα inhibitor. (20S)-Protopanaxatriol shows a broad spectrum of antitumor effects.
    (20S)-Protopanaxatriol (Standard)
  • HY-162560
    Antitumor agent-162
    		Inhibitor
    Antitumor agent-162 (compound 52a) is a potent and orally active antitumor agent. Antitumor agent-162 shows cytotoxicity.
    Antitumor agent-162
  • HY-100469
    LXRβ agonist-2
    		Agonist
    LXRβ agonist-2 is an orally active and selective LXRβ agonist. LXRβ agonist-2 increases high-density lipoprotein cholesterol levels without elevating plasma triglyceride levels. LXRβ agonist-2 decreases lipid accumulation area in the aortic arch. LXRβ agonist-2 can be used for the research of atherosclerosis.
    LXRβ agonist-2
  • HY-RS09529
    NR1H2 Human Pre-designed siRNA Set A
    		Inhibitor

    NR1H2 Human Pre-designed siRNA Set A contains three designed siRNAs for NR1H2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    NR1H2 Human Pre-designed siRNA Set A
  • HY-115780
    E17110
    		Agonist
    E17110 is a liver X receptor β (LXRβ) agonist with an EC50 of 0.72 μM. E17110 can increase the expression of ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1) in RAW264.7 macrophages. E17110 also reduce cellular lipid accumulation and promoted cholesterol efflux. E17110 can be used for the research of cardiovascular disease, such as atherosclerosis.
    E17110
  • HY-173393
    LXRα agonist 1
    		Agonist
    LXRα agonist 1 (Compound 40) is a selective LXRα agonist (EC50: 42 nM). LXRα agonist 1 also has a certain agonistic effect on LXRβ (EC50: 266 nM). LXRα agonist 1 promotes target gene transcription by stabilizing the ligand binding domain (LBD) of LXRα. LXRα agonist 1 exhibits potent antitumor effects in hepatocellular carcinoma cells when combined with the Raf inhibitor Sorafenib (HY-10201). LXRα agonist 1 can be used in the study of lipotoxic cancers.
    LXRα agonist 1
  • HY-134969
    TFCA
    		Antagonist
    TFCA is a liver X receptor α (LXRα) antagonist. TFCA inhibits ligand-activated LXRα coactivation and transcriptional expression of the downstream target genes involved in fatty acid synthesis. TFCA attenuates ligand-induced lipogenesis and fatty liver by selectively inhibiting LXRα in the liver.
    TFCA
  • HY-177890
    UAB116
    		Agonist
    UAB116 is a Liver X Receptor (LXR)/Retinoid X Receptor (RXR) agonist. UAB116 can decreases metastatic phenotype in hepatoblastoma by inhibiting the Wnt/β-Catenin pathway via upregulation of TRIM29. UAB116 can reduce proliferation, stemness and invasiveness of metastatic hepatoblastoma cells.
    UAB116
  • HY-179278
    LXR agonist 4
    		Agonist
    LXR agonist 4 is a selective LXR inverse agonist with IC50 values of 7.6 (LXRα) and 2.9 μM (LXRβ), respectively. LXR agonist 4 exhibits selectivity over RORα and FXR. LXR agonist 4 robustly suppresses SREBP1c expression without altering ABCA1 or APOE. LXR agonist 4 displays antilipogenic properties and resolves fatty acid-induced steatosis. LXR agonist 4 can be used for the research of atherosclerosis and metabolic dysfunction-associated steatotic liver disease (MASLD).
    LXR agonist 4
  • HY-RS09530
    NR1H3 Human Pre-designed siRNA Set A
    		Inhibitor

    NR1H3 Human Pre-designed siRNA Set A contains three designed siRNAs for NR1H3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    NR1H3 Human Pre-designed siRNA Set A
  • HY-N12619
    12R,13S-Dihydroxyfumitremorgin C
    		Agonist
    12R,13S-Dihydroxyfumitremorgin C (compound 1) is a LXRα agonist.
    12R,13S-Dihydroxyfumitremorgin C
  • HY-146275
    LXRβ agonist-3
    		Agonist
    LXRβ agonist-3 (compound 4-13) is a potent and selective LXRβ (liver X receptor β) agonist, with an EC50 of 0.095 μM. LXRβ agonist-3 efficiently inhibits U87EGFRvIII cell, with an IC50 of 3.75 μM. LXRβ agonist-3 shows antitumor activity, and can inhibit glioblastoma.
    LXRβ agonist-3
  • HY-139067
    25(S)-27-Hydroxy cholesterol
    		Activator
    25(S)-27-Hydroxy cholesterol is a metabolite of CYP27A1 mediated cholesterol hydroxylation. 25(S)-27-Hydroxy cholesterol inhibits melanoma cell proliferation.
    25(S)-27-Hydroxy cholesterol
  • HY-N0246R
    Saikosaponin A (Standard)
    		Activator
    Saikosaponin A (Standard) is the analytical standard of Saikosaponin A. This product is intended for research and analytical applications. Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also act as a potential peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, significantly promoting the expression of PPAR-γ. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis.
    Saikosaponin A (Standard)
  • HY-N2371R
    27-Hydroxycholesterol (Standard)
    		Agonist
    27-Hydroxycholesterol (27-OHC) is a selective estrogen receptor modulator and an agonist of the liver X receptor.
    27-Hydroxycholesterol (Standard)
  • HY-N2370R
    24-Hydroxycholesterol (Standard)
    		Activator
    24-Hydroxycholesterol is a natural sterol, which serves as a positive allosteric modulator of N-Methyl-d-Aspartate (NMDA) receptorsR, and a potent activator of the transcription factors LXR.
    24-Hydroxycholesterol (Standard)
  • HY-N3867
    Ethyl 2,4,6-trihydroxybenzoate
    		Inhibitor
    Ethyl 2,4,6-trihydroxybenzoate (Benzoic acid, 2,4,6-trihydroxy-, ethyl ester) is a Triterpenoids product that can be isolated from the herbs of Pueraria lobata.
    Ethyl 2,4,6-trihydroxybenzoate
  • HY-139576C
    Larsucosterol ammonium
    		Antagonist
    Larsucosterol (DUR-928) ammonium, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol ammonium as a potent endogenous regulator decreases lipogenesis. Larsucosterol ammonium inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1.
    Larsucosterol ammonium
  • HY-101442R
    SR9238 (Standard)
    		Antagonist
    SR9238 (Standard) is the analytical standard of SR9238. This product is intended for research and analytical applications. SR9238 is a synthetic liver X receptor (LXR) inverse agonist with IC50s of 214 nM and 43 nM for LXRα and LXRβ, respectively.
    SR9238 (Standard)
Cat. No. Nombre del producto / Synonyms Application Reactivity